Thalidomide metabolism by the CYP2C subfamily

Clinical Cancer Research

Volumn 8, Issue 6, 2002, Pages 1964-1973

  Ando, Yuichi ^a   Fuse, Eiichi ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTHALIDOMIDE; 5' HYDROXYTHALIDOMIDE; 5,6 DIHYDROXYTHALIDOMIDE; ALPHA NAPHTHOFLAVONE; ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2C11; CYTOCHROME P450 2C19; CYTOCHROME P450 2C6; CYTOCHROME P450 2C9; ISOENZYME; MEPHENYTOIN; OMEPRAZOLE; THALIDOMIDE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CANCER; CATALYSIS; DIASTEREOISOMER; ENZYME ACTIVITY; HYDROXYLATION; LIVER MICROSOME; METABOLISM; METABOLITE; PRIORITY JOURNAL;

ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; FEMALE; HUMANS; ISOENZYMES; MALE; MICE; MICROSOMES, LIVER; RABBITS; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; STEREOISOMERISM; TERATOGENS; THALIDOMIDE;

EID: 0036285336     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Thalidomide is an inhibitor of angiogenesis
2. Antitumor activity of thalidomide in refractory multiple myeloma
3. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
4. Thalidomide teratogenesis: Evidence for a toxic arene oxide metabolite
5. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: Evidence for prostaglandin H synthasecatalyzed bioactivation of thalidomide to a teratogenic reactive intermediate
6. Developmental model for thalidomide action
7. Free radical-mediated oxidative DNA damage in the mechanisms of thalidomide teratogenicity
8. Hypothesis: Thalidomide embryopathy-proposed mechanism of action
9. Teratogen metabolism: Thalidomide activation is mediated by cytochrome P-450
10. Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites
11. Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts
12. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species dependent
13. Evaluation of the developmental toxicity of thalidomide using frog embryo teratogenesis assay-Xenopus (FETAX): Biotransformation and detoxification
14. Teratogen metabolism: Spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes
15. Drug metabolism by the human fetus
16. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs
17. Effects of maternal thalidomide treatment on pregnancy, fetal development, and mortality of the offspring in random-bred mice
18. Nonconfirmation of thalidomide induced teratogenesis in rats and mice
19. Drug metabolism in the newborn rabbit
20. Inability of newborn mice and guinea pigs to metabolize drugs
21. The metabolism of thalidomide: The spontaneous hydrolysis of thalidomide in solution
22. Hydroxylated metabolites of thalidomide: Formation in vitro and in vivo in man
23. Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients
24. Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics
25. Teratogen metabolism: Activation of thalidomide and thalidomide analogues to products that inhibit the attachment of cells to concanavalin a coated plastic surfaces
26. Thalidomideinduced neuropathy and genetic differences in drug metabolism
27. Thalidomide-induced peripheral neuropathy
28. Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection
29. Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation
30. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes
31. Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis
32. Pituitary regulation of sex-specific forms of cytochrome P-450 in liver microsomes of rats
33. Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes
34. Biochemistry and molecular biology of the human CYP2C subfamily
35. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations
36. Decrease in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats
37. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
38. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes
39. Purification and characterization of liver microsomal cytochromes P-450: Electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphthoflavone
40. Effects of phenobarbital, 3-methylcholanthrene and polychlorinated biphenyls on sex-specific forms of cytochrome P-450 in liver microsomes of rats
41. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
42. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo
43. Genetic heterogeneity of angiogenesis in mice
44. Neurobehavioral teratogenic effects of thalidomide in rats
45. Pharmacogenetics
46. Cytochrome P-450 1A1 expression in human small bowel: Interindividual variation and inhibition by ketoconazole
47. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism
48. Cytochrome P450 in human fetal liver: Significance and fetal-specific expression
49. Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries
50. Metabolic characterization of the major human small intestinal cytochrome P450s
51. Characterization of rat small intestinal cytochrome P450 composition and inducibility
52. Aryl hydrocarbon hydroxylase and polycyclic hydrocarbon tumorigenesis: Effect of the enzyme inhibitor 7,8-benzoflavone on tumorigenesis and macromolecule binding
53. Differential mechanisms of cytochrome P450 inhibition and activation by α-naphthoflavone
54. Cooperativity in oxidations catalyzed by cytochrome P450 3A4